Blut

, Volume 35, Issue 4, pp 277–288 | Cite as

Interferons: Anti-neoplastic drugs?

  • H. Strander
Leading Article

Keywords

Public Health Interferon 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Adams, A., Strander, H., Cantell, K.: Sensitivity of the Epstein-Barr virus transformed human lymphoid cell lines to Interferon. J. gen. Virol.28, 207 (1975)Google Scholar
  2. 2.
    Aho, K., Strander, H., Leikola, J., Kleemola, M., Carlström, G., Cantell, K.: An inhibitor of the complement-fixation reaction associated with interferon treatment. Clin. Immunol. Inmunopath.5, 399 (1976)Google Scholar
  3. 3.
    Anfinsen, C.B., Bose, S., Corley, L., Gurari-Rothman, D.: Partial purification of human interferon by affinity chromatography. Proc. Natl. Acad. Sci. (Am.)71, 3139 (1974)Google Scholar
  4. 4.
    Ankel, H., Besançon, F.: Are gangliosides cell membrane receptors for interferon? Abstract, In: Symposium on interferons and the control of cell-virus interactions, Rehovot, Israel, May 2–6, 1977Google Scholar
  5. 5.
    Aparisi, T., Broström, L.-Å., Ingimarsson, S., Lagergren, C., Nilsonne, U., Strander, H., Söderberg, G.: Prognostic factors in osteosarcoma. Can historical controls be used in current clinical trials? Intern. J. Rad. Oncol. Biol. Phys. (in press) (1977)Google Scholar
  6. 6.
    Baron, S.: Mechanism of recovery from viral infection. Adv. Virus Res.10, 39 (1963)Google Scholar
  7. 7.
    Baron, S., Buckler, C.E.: Circulating interferon in mice after intravenous injection of virus. Science141, 1061 (1963)Google Scholar
  8. 8.
    Bekesi, J.G., Roboz, J.P., Zimmerman, E., Holland, J.F.: Treatment of spontaneous leukemia in AKR mice with chemotherapy, immunotherapy, or interferon. Cancer Res.36, 631 (1976)Google Scholar
  9. 9.
    Berg, K., Ogburn, C.A., Paucker, K., Mogensen, K.E., Cantell, K.: Affinity chromatography of human leukocyte and diploid cell interferon on sepharose-bound antibodies. J. Immunol.114, 640 (1975)Google Scholar
  10. 10.
    Blomgren, H., Cantell, K., Johansson, B., Lagergren, C., Ringborg, U., Strander, H.: Interferon therapy in Hodgkin's disease. Acta med. Scand.199, 527 (1976)Google Scholar
  11. 11.
    Brodeur, B.R., Merigan, T.C.: Mechanism of the suppressive effect of interferon on antibody synthesis in vivo. J. Immunol.114, 1323 (1975)Google Scholar
  12. 12.
    Burke, D.C.: The status of interferon. Scientific American236, 42 (1977)Google Scholar
  13. 13.
    Burke, D.C., Meager, A., Lehman, J., Stein, G.: Some control factors in the production of Interferon. Abstract, In: Symposium on interferons and the control of cell-virus interactions, Rehovot, Israel, May 2–6, 1977Google Scholar
  14. 14.
    Cantell, K.: Prospects for the clinical use of exogenous interferon. Med. Biol. (in press) (1977)Google Scholar
  15. 15.
    Cantell, K., Hirvonen, S., Mogensen, K.E., Pyhälä, L.: Human leukocyte interferon: production, purification, stability and animal experiments. In Vitro, Monograph 3, 35 (1973)Google Scholar
  16. 16.
    Cantell, K., Pyhälä, L.: Pharmacokinetics of human leukocyte interferon. J. Infect. Dis.133, Supplement A. 6 (1976)Google Scholar
  17. 17.
    Cantell, K., Pyhälä, L., Strander, H.: Circulating human interferon after intramuscular injection into animals and man. J. gen. Virol.22, 453 (1974)Google Scholar
  18. 18.
    Cantell, K., Strander, H., Hadhazy, G., Nevanlinna, H.R.: How much interferon can be prepared in human leukocyte suspensions? In: The Interferons (ed. G. Rita), pp. 223. New York-London: Academic Press 1968Google Scholar
  19. 19.
    Carter, W.A., Mikulski, A.J., Horoszewicz, J.S., Heine, J.W., Sulkowski, E.: Large scale purification and characterization of fibroblast interferon. Abstract, In: Production of human interferon and investigations of its clinical use. A symposium workshop, W. Alton Jones Cell Science Center, Lake Placid, USA, May 19–20, 1977Google Scholar
  20. 20.
    Chany, C, Chany-Fournier, F., Pauloin, A.: Constitution and functioning of the cell membrane-bound interferon receptor system. Abstract, In: Symposium on interferons, and the control of cell-virus interactions, Rehovot, Israel, May 2–6, 1977Google Scholar
  21. 21.
    Chen, J.K., Jankowski, W.J., O'Malley, J.A., Sulkowski, E., Carter, W.A.: Nature of the molecular heterogeneity of human leukocyte interferon. J. Virol.19, 425 (1976)Google Scholar
  22. 22.
    Chirigos, M.A., Pearson, J.W.: Cure of murine leukemia with drug and interferon treatment. J. Natl. Cancer Inst.51, 1367 (1973)Google Scholar
  23. 23.
    Cortes, E.P., Holland, J.F., Wang, J.J., Sinks, L.F., Blom, J., Senn, H., Bank, A., Glidewell, O.: Amputation and adriamycin in primary osteosarcoma. New Engl. J. Med.29, 998 (1974)Google Scholar
  24. 24.
    Dahl, H., Strander, H.: Human leukocyte interferon and cell growth inhibition. Quantitative differentiation following SDS-treatment. Abstract, In: Symposium on interferons and the control of cell-virus interactions, Rehovot, Israel, May 2–6, 1977Google Scholar
  25. 25.
    Davey, M.W., Sulkowski, E., Carter, W.A.: Purification and characterization of mouse interferon with novel affinity sorbents. J. Virol.17, 439 (1976)Google Scholar
  26. 26.
    De Maeyer, E., De Maeyer-Guignard, J., van De Putte, M.: Inhibition by interferon of delayed type hypersensitivity in the mouse. Proc. Natl. Acad. Sci. (Am.)72, 1753 (1975)Google Scholar
  27. 27.
    Desmyter, J., Rawls, W.E., Melnick, J.L.: A human interferon that crosses the species line. Proc. Natl. Acad. Sci. (Am.)59, 69 (1968)Google Scholar
  28. 28.
    Desmyter, J., Ray, M.B., De Groote, J., Bradburne, A.F., Desmet, V.J., Edy, V.G., Billiau, A., De Somer, P., Mortelmans, J.: Administration of human fibriblast interferon in chronic hepatitis-B infection. LancetII, 645 (1976)Google Scholar
  29. 29.
    De Somer, P.: Clinical trials with human fibroblast interferon. Abstract, In: Symposium on interferon and the control of cell-virus interactions. Rehovot, Israel, May 2–6, 1977Google Scholar
  30. 30.
    De Somer, P., Joniau, M., Edy, V.G., Billiau, A.: Mass production of human interferon in diploid cells In Vitro, Monograph3, 39 (1974)Google Scholar
  31. 31.
    Edy, V.G., Billiau, A., De Somer, P.: Large-scale production of interferon in human diploid fibroblast cells. Abstract, In: Production of human interferon and investigations of its clinical use. A symposium workshop, W. Alton Jones Cell Scisnce Center, Lake Placid, USA, May 19–20, 1977Google Scholar
  32. 32.
    Einhorn, S., Strander, H.: Is interferon tissue specific? Effect of human leukocyte and fibroblast interferons on the growth of lymphoblastoid and osteosarcoma cell lines. J. gen. Virol.35, 573 (1977)Google Scholar
  33. 33.
    Emödi, G., Rufli, T., Just, M., Hernandez, R.: Human interferon therapy for herpes zoster in adults. Scand. J. Infect. Dis.7, 1 (1975)Google Scholar
  34. 34.
    Falcoff, R.: Some properties of virus and immune-induced, human lymphocyte interferon. J. gen. Virol.16, 251 (1972)Google Scholar
  35. 35.
    Falcoff, E., Falcoff, R., Fournier, F., Chany, C.: Production en masse, purification partielle et caractérisation d'un interferon destiné à des essais thérapeutiques humain. Ann. Inst. Pasteur111, 562 (1966)Google Scholar
  36. 36.
    Falcoff, R., Lewis, J., Le-Dinh-Thai, Falcoff, E.: Protein phosphorylation and inhibition of translation of viral and synthetic messengers in extracts from interferon-treated cells. Abstract, In: Symposium on interferons and the control of cell-virus interactions, Rehovot, Israel, May 2–6, 1977Google Scholar
  37. 37.
    Fantes, K.: Purification and properties of human interferon. Ann. N.Y. Acad. Sci.173, 118 (1970)Google Scholar
  38. 38.
    Finter, N.B.: Interferons and interferon inducers. Amsterdam: North-Holland Comp. 1973Google Scholar
  39. 39.
    Finter, N.B., Fantes, K.H., Johnston, M.D., Christofinis, G., Ball, G.D.: The Namalva line of lymphoblastoid cell as a source of large amounts of human interferon. Abstract, In: Symposium on interferons and the control of cell-virus interactions, Rehovot, Israel, May 2–6, 1977Google Scholar
  40. 40.
    Frayssinet, C., Grosser, I., Tovey, M., Lindahl, P.: Inhibitory effect of potent interferon preparations on the regeneration of mouse liver after partial hepatectomy. Nature (Lond.)245, 146 (1973)Google Scholar
  41. 41.
    Friedman, R.M.: Role of interferon in viral interference. Nature (Lond.)201, 848 (1964)Google Scholar
  42. 42.
    Friedman, R.M., Ramseur, J.M.: Inhibition of murine leukemia virus production in chronically infected AKR cells; a novel effect of interferon. Proc. Natl. Acad. Sci. (Am.)71, 3542 (1974)Google Scholar
  43. 43.
    Galasso, G.J.: Interferon: Its expectations for the future. In Vitro, Monograph3, 66 (1974)Google Scholar
  44. 44.
    Gisler, R.H., Lindahl, P., Gresser, I.: Effects of interferon on antibody synthesis in vitro. J. Immunol.113, 438 (1974)Google Scholar
  45. 45.
    Glasgow, L.A.: Leukocytes and interferon in the host response to viral infections. II. Enhanced interferon response of leukocytes from immune animals. J. Bact.91, 2185 (1966)Google Scholar
  46. 46.
    Greenberg, H.B., Pollard, R.B., Lutwick, L.J., Gregory, P.B., Robinson, W.S., Merigan, T.C.: Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. New Engl. J. Med.295, 517 (1976)Google Scholar
  47. 47.
    Gresser, I.: Antitumor effects of interferon. Adv. Cancer Res.16, 97 (1972)Google Scholar
  48. 48.
    Gresser, I.: Antitumor effects of interferon. In: Cancer. A comprehensive treatise, (ed. F. Becker) (in press) 1977Google Scholar
  49. 49.
    Gresser, I., Brouty-Boyé, D., Thomas, M.-T., Macieira-Coelho, A.: Interferon and cell division. II. Influence of various experimental conditions on the inhibition of L1210 cell multiplication in vitro by interferon preparations. J. Natl. Cancer Inst.45, 1145 (1970)Google Scholar
  50. 50.
    Gresser, I., Maury, C., Brouty-Boyé, D.: On the mechanism of the antitumour effect of interferon in mice. Nature (Lond.)239, 167 (1972)Google Scholar
  51. 51.
    Grossberg, S.E.: The interferons and their inducers: molecular and therapeutic considerations. New Engl. J. Med.287, 13, 79, 122 (1972)Google Scholar
  52. 52.
    Grossberg, S.E., Sela, I., Sedmak, J.J., Mehler, A.H.: Biological characterization of the deacylating factor induced by interferon. Abstract, In: Symposium on interferons and the control of cell-virus interactions, Rehovot, Israel, May 2–6, 1977Google Scholar
  53. 53.
    Habif, D.V., Lipton, R., Cantell, K.: Interferon crosses blood-cerebrospinal fluid barrier in monkeys. Proc. Soc. Exptl. Biol. Med.149, 287 (1975)Google Scholar
  54. 54.
    Havell, E.A., Berman, B., Ogburn, C.A., Berg, K., Paucker, K., Vilček, J.: Two antigenically distinct species of human interferon. Proc. Natl. Acad. Sci. (Am.)72, 2185 (1975)Google Scholar
  55. 55.
    Havell, E.A., Vilcek, J.: Production of high-titred interferon in cultures of human diploid cells. Antimicrob. Ag. Chemother.2, 476 (1972)Google Scholar
  56. 56.
    Havell, E.A., Vilček, J.: Mass production and some characteristics of human interferon from diploid cells. In Vitro, Monograph3, 47 (1974)Google Scholar
  57. 57.
    Hilfenhaus, J., Karges, H.E.: Growth inhibition of human lymphoblastoid cells by interferon preparations obtained from human leukocytes. Z. Naturforsch.29, 618 (1974)Google Scholar
  58. 58.
    Hilleman, M.R.: Interferon in prospect and perspective. J. Cell, and Comp. Physiol.62, 337 (1963)Google Scholar
  59. 59.
    Ho, M., Armstrong, J.A.: Interferon. Ann. Rev. Microbiol.29, 131 (1975)Google Scholar
  60. 60.
    Ho, M., Postic, B.: Renal excretion of interferon. Nature (Lond.)214, 1230 (1967)Google Scholar
  61. 61.
    Hopps, H.E.: Potential safety requirements for human interferon. In Vitro, Monograph3, 63 (1974)Google Scholar
  62. 62.
    Huang, K.-Y., Donahoe, R.M., Gordon, F.B., Dressler, H.R.: Enhancement of phagocytosis by interferon containing preparations. Infection and Immunity4, 581 (1971)Google Scholar
  63. 63.
    Ikic, D., Bosnie, N., Smerdel, S., Jusić, D., Šooš, E., Delimar, N.: Double blind clinical study with human leukocyte interferon in the therapy of condylomata acuminata. Proc. Symp. on Clinical Use of Interferon, Zagreb, Yugoslavia, October 1–2, 1975Google Scholar
  64. 64.
    Ikić, D., Krusić, J., Cupale, K., Car, D., Rogulić, A., Jakasa, V., Jusić, D., Šooš, E., Turner, V.: The use of human leukocytic interferon in patients with cervical cancer and baseocellular cancer of the skin. Proc. Symp. on Clinical Use of Interferon, Zagreb, Yugoslavia, October 1–2, 1975Google Scholar
  65. 65.
    Ikić, D., Petricević, J., Soldo, J., Šooš, E., Smerdel, S., Jusić, D.: Treatment of influenza with human leukocytic interferon. Proc. Symp. on Clinical Use of Interferon, Zagreb, Yugoslavia, October 1–2, 1975Google Scholar
  66. 66.
    Isaacs, A.: Interferon. Adv. Virus Res.10, 1 (1963)Google Scholar
  67. 67.
    Isaacs, A., Lindenmann, J.: Virus interference. I. The Interferon. Proc. Roy. Soc. Ser. B.147, 258 (1957)Google Scholar
  68. 68.
    Jaffe, N., Frei, E., Traggis, D., Bishop, Y.: Adjuvant methohexate and citrovorum-factor treatment of osteogenic sarcoma. New Engl. J. Med.291, 994 (1974)Google Scholar
  69. 69.
    Jankowski, W.J., Davey, M.W., O'Malley, J.A., Sulkowski, E., Carter, E.A.: Molecular structure of human fibroblast and leukocyte interferons: Probe by lectin and hydrophobic chromatography. J. Virol.16, 1124 (1975)Google Scholar
  70. 70.
    Johnson, H.M., Smith, B.G., Baron, S.: Inhibition of the primary in vitro antibody response by interferon preparations. J. Immunol.114, 403 (1975)Google Scholar
  71. 71.
    Johnston, M.D., Finter, N.B.: Production of human lymphoblastoid interferon. Abstract in: Production of human interferon and investigations of its clinical use. A symposium workshop, W. Alton Jones Cell Science Center, Lake Placid, USA, May 19–20, 1977Google Scholar
  72. 72.
    Joklik, W.K.: The effect of interferon on the multiplication of Reovirus. Abstract, In: Symposium on interferons and the control of cell-virus interaction, Rehovot, Israel, May 2–6, 1977Google Scholar
  73. 73.
    Jones, B.R., Coster, D.J., Falcon, M.G., Cantell, K.: Topical therapy of ulcerative herpetic keratitis with human interferon. LancetII, 128 (1976)Google Scholar
  74. 74.
    Jordan, G.W., Fried, R.P., Merigan, T.C.: Administration of human leukocyte interferon in herpes zoster. I. Safety, circulating antiviral activity, and host responses to infection. J. Infect. Dis.130, 56 (1974)Google Scholar
  75. 75.
    Jungwirth, C., Kroath, H., Osterhoff, J., Gross, H., Bodo, G.: The regulation of poxvirusspecific protein synthesis in the interferon-treated chick-embryo cell. Abstract, In: Symposiumon interferons and the control of cell-virus interactions, Rehovot, Israel, May 2–6, 1977Google Scholar
  76. 76.
    Kassel, R.L., Old, L.J., Carswell, E.A., Fiore, N., Hardy Jr., W.D.: Serum-mediated leukemia cell destruction in AKR mice. J. Exptl. Med.138, 925 (1973)Google Scholar
  77. 77.
    Kishida, T., Sotomatsu, S., Uyeda, K., Matsuo, A., Negoro, Y., Imanishi, J., Ito, H.: Human leukocyte interferon and its clinical evaluation. Proc. Symp. on Clinical use of Interferon, Zagreb, Yugoslavia, October 1–2, 1975Google Scholar
  78. 78.
    Knight, E.: Heterogeneity of purified mouse interferons. J. biol. Chem.250, 4139 (1975)Google Scholar
  79. 79.
    Knight, E.: Interferon: purification and initial characterization from human diploid cells. Proc. Natl. Acad. Sci. (Am.)73, 520 (1976)Google Scholar
  80. 80.
    Kuwata, T., Fuse, A., Moringaga, N.: Effect of cycloheximide and puromycin on the antiviral and anticellular activities of human interferon. (in press) 1977Google Scholar
  81. 81.
    Levine, D.W.: New microcarriers for the large scale production of normal anchoragedependent mammalian cells. Abstract, in: Production of human interferon and investigations of its clinical use. A symposium workshop, W. Alton Jones Cell Science Center, Lake Placid, USA, May 19–20, 1977Google Scholar
  82. 82.
    Levy, H.B.: Studies on control of disease with a stabilized Poly I. Poly C. Abstract, in: Symposium on interferons and the control of cell-virus interactions, Rehovot, Israel, May 2–6, 1977Google Scholar
  83. 83.
    Levy, H.B., Baer, G., Baron, S., Buckler, C.E., Gibbs, C.J., Iadarola, M.J., London, W.T., Rice, J.: A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J. Infect. Dis.132, 434 (1975)Google Scholar
  84. 84.
    Levy, M.H., Wheelock, E.F.: Impaired macrophage function in Friend virus leukemia: restoration by Statolon. J. Immunol.114, 962 (1975)Google Scholar
  85. 85.
    Lindahl, P.: Influence of Interferon on normal cell functions. Thesis, Balder AB, Stockholm, 1974Google Scholar
  86. 86.
    Lockart Jr., R.Z.: Recent progress in research on interferons. Progr. med. Virol.9, 451 (1967)Google Scholar
  87. 87.
    Marcus, P.J., Sekallick, M.J.: The Interferon system: Interferon induction by a defective interfering particle with covalently linked ± RNA, and its sparing effect on cell killing by viruses. Abstract, in: Symposium on interferons and the control of cell-virus interactions, Rehovot, Israel, May 2–6, 1977Google Scholar
  88. 88.
    Matsuo, A., Hayashi, S., Kishida, T.: Production and purification of human leukocyte interferon. Japan. J. Microbiol.18, 21 (1974)Google Scholar
  89. 89.
    Merigan, T.C.: Interferon: Its inducers and some aspects of host resistance in malignancy. Cancer Chemotherapy Rep.58, 571 (1974)Google Scholar
  90. 90.
    Merigan, T.C. (ed.): Antivirals with clinical potential. J. Infect. Dis.133, Supplement (1976)Google Scholar
  91. 91.
    Merigan, T.C., Hall, T.S., Reed, S.E., Tyrrell, D.A.J.: Inhibition of respiratory virus infection by locally applied interferon. LancetI, 563 (1973)Google Scholar
  92. 92.
    Merigan, T.C., Jordan, G.W., Fried, R.P.: Clinical utilization of exogenous human interferon. Persp. Virol.9, 249 (1975)Google Scholar
  93. 93.
    Metz, D.: Interferon: the anti-viral puzzle. New Scientist, 328 (1975)Google Scholar
  94. 94.
    Mogensen, K.E., Cantell, K.: Production and preparation of human leukocyte interferon. Pharmacology and Therapeutics (in press) (1977)Google Scholar
  95. 95.
    Morgan, M.J., Faik, P.: The expression of the interferon system in clones of Chinese hamster/ human hybrid cells. Abstract, in: Symposium on interferons and the control of cell-virus interactions, Rehovot, Israel, May 2–6, 1977Google Scholar
  96. 96.
    Nagano, Y.: Virus-inhibiting factor. University of Tokyo Press 1975Google Scholar
  97. 97.
    O'Shaughnessy, M.V., Easterbrook, K.B., Lee, S.H.S., Katz, L.J., Rozee, K.R.: Interferon inhibition of autogenously induced virions (C particles) in synchronized L-929 cell cultures. J. Natl. Cancer Inst.53, 1687 (1974)Google Scholar
  98. 98.
    Pallin, O., Lundmark, K.-M., Brege, K.G.: Interferon in severe herpes simplex of the cornea. LancetI, 1187 (1976)Google Scholar
  99. 99.
    Paucker, K., Dalton, B.-J., Ogburn, C.A., Törmä, E.: Multiple active sites on human interferons. Proc. Natl. Acad. Sci. (Am.)72, 4587 (1975)Google Scholar
  100. 100.
    Paucker, K., Dalton, B.J., Törmä, E.T.: Similar biological properties of two major components in human leukocyte interferon. Abstract, in: Symposium on interferons and the control of cell-virus interactions, Rehovot, Israel, May 2–6, 1977Google Scholar
  101. 101.
    Pestka, S., McInnes, J., Havell, E.A., Vilček, J.: Cell-free synthesis of human interferon. Proc. Natl. Acad. Sci. (Am.)72, 3898 (1975)Google Scholar
  102. 102.
    Pitha, P., Raj, B., Reynolds, F., Reddy, P.: Relationship between interferon production and interferon mRNA synthesis in human flbroblasts. Abstract, in: Symposium on interferons and the control of cell-virus interactions, Rehovot, Israel, May 2–6, 1977Google Scholar
  103. 103.
    Pitha, P.M., Rowe, W.P., Oxman, M.N.: Effect of interferon on exogenous, endogenous and chronic murine leukemia virus infection. Virology70, 324 (1976)Google Scholar
  104. 104.
    Purcell, R.H., London, W.T., McAuliffe, M., Palmer, A.E., Kaplan, P.M., Gerin, J.L., Wagner, J., Popper, H., Lvovsky, E., Wong, D.C., Levy, H.B.: Modification of chronic hepatitis-B virus infection in chimpanzees by administration of an interferon inducer. LancetII, 757 (1976)Google Scholar
  105. 105.
    Revel, M., Bash, D., Ruddle, F.H.: Antibodies to a cell-surface component coded by human chromosome 21 inhibit action of interferon. Nature (Lond.)230, 139 (1976)Google Scholar
  106. 106.
    Revel, M., Kimchi, A., Schmidt, A., Zilberstein, A., Gilboa, E., Shulman, L., Federman, P.: Regulation of the interferon-induced specific protein phosphorylation and translational inhibition in mouse L. cells. Abstract, in: Symposium on interferons and the control of cellvirus interactions, Rehovot, Israel, May 2–6, 1977Google Scholar
  107. 107.
    Salerno, R.A., Whitmire, C.E., Garcia, I.M., Huebner, R.J.: Chemical carcinogenesis in mice inhibited by interferon. Nature New Biology239, 31 (1972)Google Scholar
  108. 108.
    Salzer, M., Salzer-Kuntschik, M., Zhuber, K., Price, C.H.G., Willert, H.G., Immenkamp, M., Matejovsky, Z., Groh, P., Keyl, W.: Therapie und Prognose des kindlichen Osteosarkoms. Arch. orthop. Unfall-Chir.85, 279 (1976)Google Scholar
  109. 109.
    Sen, G.C., Ratner, L., Desrosiers, R., Dubois, M., Kawakita, M., Cabrer, B., Slaffery, E., Taira, H., Wiegand, R., Lengyel, P.: Interferon, double-stranded RNA, protein phosphorylation and RNA degradation. Abstract, in: Symposium on interferons and the control of cellvirus interactions, Rehovot, Israel, May 2–6, 1977Google Scholar
  110. 110.
    Soloviev, V.D.: The results of controlled observations on the prophylaxis of influenza with interferon. Bull. WHO41, 633 (1969)Google Scholar
  111. 111.
    Spina, C.A., Chang, R.S., Mishra, L., Golden, H.D.: Interferon production by human cells in vitro. Appl. Microbiol.24, 735 (1972)Google Scholar
  112. 112.
    Stewart II, W.E., DeClercq, E., De Somer, P.: Recovery of cell-bound interferon. J. Virol.10, 707 (1972)Google Scholar
  113. 113.
    Stewart II, W.E., Gosser, L.B., Lockart Jr., R.Z.: Priming: a nonantiviral function of interferon. J. Virol.7, 792 (1971)Google Scholar
  114. 114.
    Stewart II, W.E., Gresser, I., Tovey, M.G., Bandu, M.T., Le Goff, S.: Identification of the cell multiplication inhibitory factors in interferon preparations as interferon. Nature (Lond.)262, 300 (1976)Google Scholar
  115. 115.
    Stewart II, W.E., Lin, L., Chudzio, T., Wiranowsky-Stewart, M.: Human leukocyte interferons: Analysis of size and charge heterogeneities by SDS-PAGE, ion-exchange chromatography isoelectric focusing, and two-dimensional gel electrophoresis. Abstract, in: Symposium on interferons and the control of cell-virus interactions, Rehovot, Israel, May 2–6, 1977Google Scholar
  116. 116.
    Stinebring, W.R.: Introduction: The interferon system. In Vitro, Monograph3, 1 (1974)Google Scholar
  117. 117.
    Strander, H.: Anti-tumour effects of interferon and its possible use as an anti-neoplastic agent in man. Texas Rep. Biol. Med. (in press) (1977)Google Scholar
  118. 118.
    Strander, H., Cantell, K.: Production of interferon by human leukocytes in vitro. Ann. med. exp. biol. Fenn.44, 265 (1966)Google Scholar
  119. 119.
    Strander, H., Cantell, K.: Studies on antiviral and antitumor effects of human leukocyte interferon in vitro and in vivo. In Vitro, Monograph3, 49 (1974)Google Scholar
  120. 120.
    Strander, H., Cantell, K., Carlström, G., Ingimarsson, S., Jakobsson, P.A., Nilsonne, U.: Acute infections in interferon-treated patients with osteosarcoma: preliminary report of a comparative study. J. Infect. Dis.133, Supplément A, 245 (1976)Google Scholar
  121. 121.
    Strander, H., Cantell, K., Carlström, G., Jakobsson, P.Å.: Systemic administration of potent interferon to patients with malignant diseases. J. Natl. Cancer Inst.51, 733 (1973)Google Scholar
  122. 122.
    Strander, H., Cantell, K., Ingimarsson, S., Jakobsson, P.Å., Nilsonne, U., Söderberg, G.: Interferon treatment of osteogenic sarcoma: a clinical trial. Fogarty Intern. Center Proc. (Washington D.C.)28, 377 (1977)Google Scholar
  123. 123.
    Strander, H., Cantell, K., Jakobsson, P.Å., Nilsonne, U., Söderberg, G.: Exogenous interferon therapy of osteogenic sarcoma. Acta Orthop. Scand.45, 958 (1974)Google Scholar
  124. 124.
    Strander, H., Einhorn, S.: Effect of human leukocyte interferon on the growth of human osteosarcoma cells in tissue culture. Int. J. Cancer19, 468 (1977)Google Scholar
  125. 125.
    Strander, H., Mogensen, K.E., Cantell, K.: Production of human lymphoblastoid interferon. J. Clin. Microbiol.1, 116 (1975)Google Scholar
  126. 126.
    Sundmacher, R., Neumann-Haefelin, D., Cantell, K.: Successful treatment of dendritic keratitis with human leukocyte interferon. Albrect von Graefes. Arch. Klin. Ophtalmol.201, 39 (1976)Google Scholar
  127. 127.
    Tan, Y.H.: Chromosome 21 and the cell growth inhibitory effect of human interferon preparations. Nature (Lond.)260, 141 (1976)Google Scholar
  128. 128.
    Tan, Y.H., Berthold, W.: A mechanism for the induction and regulation of human fibroblastoid interferon genetic expression. J. gen. Virol.34, 401 (1977)Google Scholar
  129. 129.
    Tan, Y.H., Berthold, W.R.: Regulations of the human interferon system. Abstract, in: Symposium on interferons and the control of cell-virus interactions, Rehovot, Israel, May 2–6, 1977Google Scholar
  130. 130.
    Tan, Y.H., Creagan, R.P., Ruddle, F.H.: The somatic cell genetics of human interferon: assignment of human interferon loci to chromosomes 2 and 5. Proc. Natl. Acad. Sci. (Am.)71, 2251 (1974)Google Scholar
  131. 131.
    Tan, Y.H., Tischfield, J., Ruddle, F.H.: The linkage of genes for the human interferoninduced antiviral protein and indophenol oxidase-B traits to chromosome G-21. J. Exptl. Med.137, 317 (1973)Google Scholar
  132. 132.
    Tovey, M.G., Begon-Lours, J., Gresser, I.: A method for the large scale production of potent interferon preparations. Proc. Soc. Exptl. Biol. Med.146, 809 (1974)Google Scholar
  133. 133.
    Vilcek, J.: Interferon. Wien-New York: Springer 1969Google Scholar
  134. 134.
    Vilcek, J.: Protein chemistry and molecular biology of interferons: A secular view. Abstract, In: Symposium on interferons and the control of cell-virus interactions, Rehovot, Israel, May 2–6, 1977Google Scholar
  135. 135.
    Vilcek, J., Havell, E.A.: Stabilization of interferon messenger RNA activity by treatment of cells with metabolic inhibitors and lowering of the incubation temperature. Proc. Natl. Acad. Sci. (Am.)70, 3909 (1973)Google Scholar
  136. 136.
    Wagner, R.R.: Interferon. A review and analysis of recent observations. Amer. J. Med.38, 726 (1965)Google Scholar
  137. 137.
    Wagner, R.R., Emerson, S.U., Dubovi, E.J.: Molecular events in the infections cycle of vesicular stomatitis virus (VSV). Abstract, in: Symposium on interferons and the control of cell-virus interactions, Rehovot, Israel, May 2–6, 1977Google Scholar
  138. 138.
    Wheelock, E.F.: Interferon-like virus inhibitor induced in human leukocytes by phytohemagglutinin. Science149, 310 (1965)Google Scholar
  139. 139.
    Wheelock, E.F., Sibley, W.A.: Circulating virus, interferon and antibody after vaccination with the 17-D strain of yellow-fever virus. New Engl. J. Med.273, 194 (1965)Google Scholar
  140. 140.
    Yaron, M., Yaron, I., Gurari-Rotman, D., Revel, M., Lindner, H.R., Zur, K.: Stimulation of prostaglandin E production in human cultured fibroblasts by poly(I)-poly(C) and human interferon. Abstract, in: Sympsium on interferons and the control of cell-virus interactions, Rehovot, Israel, May 2–6, 1977Google Scholar
  141. 141.
    Youngner, J.S., Salvin, S.B.: Production and properties of migration inhibitory factor and interferon in the circulation of mice with delayed hypersensitivity. J. Immunol.111, 1914 (1973)Google Scholar
  142. 142.
    Åhström, L., Dohlwitz, A., Strander, H., Carlström, G., Cantell, K.: Interferon in acute leukaemia in children. LancetI, 166 (1974)Google Scholar

Copyright information

© Springer-Verlag 1977

Authors and Affiliations

  • H. Strander
    • 1
  1. 1.RadiumhemmetKarolinska HospitalStockholmSweden

Personalised recommendations